A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Advanced Solid Tumors

In brief

The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.

Key facts

Study ID

NCT00708006

Run by

Human Genome Sciences Inc.

People needed

66

Starts

2008-05-01

Expected to finish

2012-01-01

Last updated by the study team

2013-11-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed advanced solid malignancy
• Life expectancy of at least 3 months
• Age 18 years or older
• Acceptable liver function
• Acceptable renal function
• Acceptable hematologic status

You may not qualify if…

• Received investigational (not yet approved by a regulatory authority)agent within 4 weeks before enrollment.
• Received non-investigational agent within 3 weeks before enrollment.
• Progressive CNS involvement including the need of corticosteroids
• Pregnant or breast-feeding women
• Active, uncontrolled bacterial, viral, or fungal infections within 2 weeks of Cycle 1 Day 1
• Known HIV infection

Where it is running

• Stanford University Dept. of Medicine-Oncology — Stanford, California, United States
• University of Colorado Health Sciences Center — Aurora, Colorado, United States
• The Sarah Cannon Research Institute — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.